Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Aldeyra Therapeutics' Phase 2 Trial Of ADX-629 For Atopic Dermatitis Shows Statistically Significant And Clinically Relevant Improvement In Investigator-assessed And Patient-reported Outcomes Across Different Physiological And Psychosocial Assessments

Author: Benzinga Newsdesk | December 19, 2023 08:06am

Posted In: ALDX